Stock Price

Nektar Therapeutics secures a massive $400M offering, signaling strong investor faith in its lead drug, rezpegaldesleukin, for autoimmune diseases.

At a key summit, Candel Therapeutics will showcase how its oncolytic virus, CAN-3110, uses biomarkers to fight one of the deadliest brain cancers.

Investors await Alkane's H1 results for insights on its post-merger performance, Boda-Kaiser project, and standing in a surging commodities market.

Following a landmark FDA approval, IceCure Medical's long-serving CFO is exiting, placing the company at a pivotal financial crossroads for its new treatment.

With its lead drug in Phase 3, Celldex will update investors at three major conferences, highlighting its immunology pipeline and financial strategy.

Fresh off its Nasdaq debut, adtech firm EVA Live is betting on its new NeuroServer AI, shelving a stock sale and eyeing a buyback to fuel growth.

With a promising spinal cord injury drug nearing late-stage trials, NervGen appoints interim leader Dr. Adam Rogers as permanent CEO to guide the breakthrough.

Semiconductor leader Astera Labs launches a new R&D hub in Israel, hiring top tech veterans to develop next-gen connectivity for the demanding AI era.

A new class action lawsuit alleges Paysafe misled investors about major client risks and industry vulnerabilities, leading to a massive 27% stock drop.

Struggling garment and logistics firm Addentax Group announces a radical pivot, proposing to acquire an AI-powered crypto wealth platform in a bold move.

Amid Chapter 11 liquidation, LiDAR firm Luminar sells off key assets to pay creditors, offering to buy back senior notes at a premium.

Canadian biotech Satellos Bioscience seeks a Nasdaq listing and a $50M public offering to advance its promising muscle regeneration drug for Duchenne.

A health-tech firm with a mission for free care and a $1.3B valuation eyes a Nasdaq listing, but its revenue-free history raises critical questions.

Volvo Cars' Q4 profits fell, but a tough cost-cutting plan boosted cash flow, setting the stage for its critical electric vehicle push in a tough market.

The semiconductor giant posted a huge Non-GAAP profit but a stunning IFRS loss for 2025. What's behind the numbers and why are investors cheering?

With its lead drug MOLBREEVI under FDA review, Savara's upcoming investor talks are a critical test of its path from clinical trials to market.

Automotive seating giant Adient boosts its 2026 forecast, banking on strong North American production and operational gains, despite a reported net loss.

As Telix prepares its 2025 financials, all eyes are on its blockbuster revenue, pipeline progress, and its leading role in the booming radiopharma sector.

National imaging giant RadNet has acquired Northwest Radiology's six centers, marking its entry into Indiana and signaling a major shift for the Midwest market.

Powersports giant Massimo Group's stock plummets after announcing a bold but risky plan to acquire an AI firm and enter the health robotics market.